Fig 1.
Flow chart presenting the selection of eligible studies.
Fig 2.
A) Risk of bias summary. Review authors' judgments about each risk of bias item for each included study. B) Risk of bias graph. Review authors' judgments about each risk of bias item presented as percentages across all included studies.
Fig 3.
Overall analysis of disability progression in placebo-control randomized clinical trials of different disease modifying therapies in patients with relapsing-remitting multiple sclerosis.
Fig 4.
Subgroup analysis according to the current categorization of eligible disease modifying therapies as “first line” and “second line” drug options for the treatment of relapsing-remitting multiple sclerosis.
Fig 5.
Subgroup analysis according to the route of administration (injectable vs. oral) of eligible disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis.